Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014

Alexandra L. Tabakin; Brian M. Shinder; Sinae Kim; Zorimar Rivera-Nunez; Charles F. Polotti; Parth K. Modi; Joshua A. Sterling; Nicholas J. Farber; Kushan D. Radadia; Rahul R. Parikh; Isaac Y. Kim; Biren Saraiya; Tina M. Mayer; Eric A. Singer; Thomas L. Jang

doi:10.1016/j.clgc.2019.10.018

Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014

Alexandra L. Tabakin
, Brian M. Shinder
, Sinae Kim
, Zorimar Rivera-Nunez
, Charles F. Polotti
, Parth K. Modi
, Joshua A. Sterling
, Nicholas J. Farber
, Kushan D. Radadia
, Rahul R. Parikh
, Isaac Y. Kim
, Biren Saraiya
, Tina M. Mayer
, Eric A. Singer
, Thomas L. Jang

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

The role of retroperitoneal lymph node dissection (RPLND) as first-line treatment for stage I or IIA/B testicular seminoma is not well defined. Using the National Cancer Data Base, we identified 365 men from 2004 to 2014 who received RPLND as primary treatment for testicular seminoma and found 5-year overall survival rates of 97.3% and 92.0% for those with stage I and IIA/B disease, respectively.

Original language	English
Pages (from-to)	e194-e201
Journal	Clinical Genitourinary Cancer
Volume	18
Issue number	2
DOIs	https://doi.org/10.1016/j.clgc.2019.10.018
State	Published - Apr 2020
Externally published	Yes

Keywords

Outcomes
Overall survival
RPLND
Surgery
Testicular cancer

Access to Document

10.1016/j.clgc.2019.10.018

Cite this

Tabakin, A. L., Shinder, B. M., Kim, S., Rivera-Nunez, Z., Polotti, C. F., Modi, P. K., Sterling, J. A., Farber, N. J., Radadia, K. D., Parikh, R. R., Kim, I. Y., Saraiya, B., Mayer, T. M., Singer, E. A., & Jang, T. L. (2020). Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014. Clinical Genitourinary Cancer, 18(2), e194-e201. https://doi.org/10.1016/j.clgc.2019.10.018

@article{bd45be45970b4ca59389f9aa634a53ec,

title = "Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014",

abstract = "The role of retroperitoneal lymph node dissection (RPLND) as first-line treatment for stage I or IIA/B testicular seminoma is not well defined. Using the National Cancer Data Base, we identified 365 men from 2004 to 2014 who received RPLND as primary treatment for testicular seminoma and found 5-year overall survival rates of 97.3\% and 92.0\% for those with stage I and IIA/B disease, respectively.",

keywords = "Outcomes, Overall survival, RPLND, Surgery, Testicular cancer",

author = "Tabakin, \{Alexandra L.\} and Shinder, \{Brian M.\} and Sinae Kim and Zorimar Rivera-Nunez and Polotti, \{Charles F.\} and Modi, \{Parth K.\} and Sterling, \{Joshua A.\} and Farber, \{Nicholas J.\} and Radadia, \{Kushan D.\} and Parikh, \{Rahul R.\} and Kim, \{Isaac Y.\} and Biren Saraiya and Mayer, \{Tina M.\} and Singer, \{Eric A.\} and Jang, \{Thomas L.\}",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2020",

month = apr,

doi = "10.1016/j.clgc.2019.10.018",

language = "English",

volume = "18",

pages = "e194--e201",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

publisher = "Elsevier Inc.",

number = "2",

}

Tabakin, AL, Shinder, BM, Kim, S, Rivera-Nunez, Z, Polotti, CF, Modi, PK, Sterling, JA, Farber, NJ, Radadia, KD, Parikh, RR, Kim, IY, Saraiya, B, Mayer, TM, Singer, EA & Jang, TL 2020, 'Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014', Clinical Genitourinary Cancer, vol. 18, no. 2, pp. e194-e201. https://doi.org/10.1016/j.clgc.2019.10.018

Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014. / Tabakin, Alexandra L.; Shinder, Brian M.; Kim, Sinae et al.
In: Clinical Genitourinary Cancer, Vol. 18, No. 2, 04.2020, p. e194-e201.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma

T2 - Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014

AU - Tabakin, Alexandra L.

AU - Shinder, Brian M.

AU - Kim, Sinae

AU - Rivera-Nunez, Zorimar

AU - Polotti, Charles F.

AU - Modi, Parth K.

AU - Sterling, Joshua A.

AU - Farber, Nicholas J.

AU - Radadia, Kushan D.

AU - Parikh, Rahul R.

AU - Kim, Isaac Y.

AU - Saraiya, Biren

AU - Mayer, Tina M.

AU - Singer, Eric A.

AU - Jang, Thomas L.

PY - 2020/4

Y1 - 2020/4

N2 - The role of retroperitoneal lymph node dissection (RPLND) as first-line treatment for stage I or IIA/B testicular seminoma is not well defined. Using the National Cancer Data Base, we identified 365 men from 2004 to 2014 who received RPLND as primary treatment for testicular seminoma and found 5-year overall survival rates of 97.3% and 92.0% for those with stage I and IIA/B disease, respectively.

AB - The role of retroperitoneal lymph node dissection (RPLND) as first-line treatment for stage I or IIA/B testicular seminoma is not well defined. Using the National Cancer Data Base, we identified 365 men from 2004 to 2014 who received RPLND as primary treatment for testicular seminoma and found 5-year overall survival rates of 97.3% and 92.0% for those with stage I and IIA/B disease, respectively.

KW - Outcomes

KW - Overall survival

KW - RPLND

KW - Surgery

KW - Testicular cancer

UR - https://www.scopus.com/pages/publications/85076236923

U2 - 10.1016/j.clgc.2019.10.018

DO - 10.1016/j.clgc.2019.10.018

M3 - Article

C2 - 31818649

AN - SCOPUS:85076236923

SN - 1558-7673

VL - 18

SP - e194-e201

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 2

ER -

Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014

Abstract

Keywords

Access to Document

Fingerprint

Cite this